Evidence of altered homocysteine metabolism in chronic renal failure

被引:44
作者
Henning, BF
Riezler, R
Tepel, M
Langer, K
Raidt, H
Graefe, U
Zidek, W
机构
[1] Ruhr Univ Bochum, Marienhosp Herne, Med Klin 1, D-44625 Herne, Germany
[2] Severi Med Gmbh, Munster, Germany
[3] KfH Dialysis Ctr, Munster, Germany
来源
NEPHRON | 1999年 / 83卷 / 04期
关键词
chronic renal failure; homocysteine metabolism; alterations; homocysteine levels;
D O I
10.1159/000045423
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
The fasting serum concentrations of total homocysteine and metabolites of transsulfuration (cystathionine, cysteine, methylmalonic acid, 2-methylcitric acid) and remethylation (methionine) were determined by gas chromatography-mass spectrometry in 40 nondialyzed patients with chronic renal disease and in 50 patients with end-stage renal disease requiring chronic maintenance hemodialysis. The nondialyzed patients and 28 of the dialysis patients did not receive additional vitamin supplementations. Twenty-two of the dialysis patients received daily oral vitamin preparations containing 10 mg pyridoxine (vitamin B-6), 6 mu g cyanocobalamin (vitamin B-12), and 1 mg folic acid. In the nondialyzed patients, linear regression analysis showed positive correlations between serum concentrations of creatinine and total homocysteine (r = 0.68, p < 0.0001), cystathionine (r = 0.73, p < 0.0001), methylmalonic acid (r = 0.77, p < 0.0001), and 2-methylcitric acid (r = 0.81, p < 0.0001). Serum homocysteine was positively correlated with serum concentrations of cystathionine (r = 0.59, p < 0.0001), cysteine (r = 0.69, p = 0.004), methylmalonic acid (r = 0.64, p = 0.0001), and 2-methylcitric acid (r = 0.64, p < 0.0001). There was no significant correlation between serum concentrations of homocysteine and methionine (r = -0.14, p = 0.63). In the hemodialysis patients receiving oral vitamin supplementation, serum homocysteine and cystathionine concentrations were significantly lower than in hemodialysis patients not receiving vitamins (homocysteine 21.8 +/- 1.1 vs. 33.2 +/- 3.7 mu mol/l, p 0.0004; cystathionine 2,075.9 +/- 387.1 vs. 3,171.3 +/- 680.2 nmol/l, p = 0.02; mean +/- SEM). In summary, our results show increased intermediate products of the transsulfuration pathway, but no increase in remethylation of homocysteine in chronic renal disease, including end-stage renal disease requiring chronic maintenance dialysis. Copyright (C) 1999 S. Karger AG, Basel.
引用
收藏
页码:314 / 322
页数:9
相关论文
共 47 条
[1]   SERUM BETAINE, N,N-DIMETHYLGLYCINE AND N-METHYLGLYCINE LEVELS IN PATIENTS WITH COBALAMIN AND FOLATE-DEFICIENCY AND RELATED INBORN-ERRORS OF METABOLISM [J].
ALLEN, RH ;
STABLER, SP ;
LINDENBAUM, J .
METABOLISM-CLINICAL AND EXPERIMENTAL, 1993, 42 (11) :1448-1460
[2]   ELEVATION OF 2-METHYLCITRIC ACID-I AND ACID-II LEVELS IN SERUM, URINE, AND CEREBROSPINAL-FLUID OF PATIENTS WITH COBALAMIN DEFICIENCY [J].
ALLEN, RH ;
STABLER, SP ;
SAVAGE, DG ;
LINDENBAUM, J .
METABOLISM-CLINICAL AND EXPERIMENTAL, 1993, 42 (08) :978-988
[3]  
ARNADOTTIR M, 1993, CLIN NEPHROL, V40, P236
[4]   Hyperhomocysteinemia in cyclosporine-treated renal transplant recipients [J].
Arnadottir, M ;
Hultberg, B ;
Vladov, V ;
NilssonEhle, P ;
Thysell, H .
TRANSPLANTATION, 1996, 61 (03) :509-512
[5]  
BACHMANN J, 1995, J AM SOC NEPHROL, V6, P121
[6]   HEPATIC SULFUR AMINO-ACID-METABOLISM IN RATS WITH CHRONIC-RENAL-FAILURE [J].
BOCOCK, MA ;
ZLOTKIN, SH .
JOURNAL OF NUTRITION, 1990, 120 (07) :691-699
[7]   HYPERHOMOCYSTEINEMIA AND TRADITIONAL CARDIOVASCULAR-DISEASE RISK-FACTORS IN END-STAGE RENAL-DISEASE PATIENTS ON DIALYSIS - A CASE-CONTROL STUDY [J].
BOSTOM, AG ;
SHEMIN, D ;
LAPANE, KL ;
MILLER, JW ;
SUTHERLAND, P ;
NADEAU, M ;
SEYOUM, E ;
HARTMAN, W ;
PRIOR, R ;
WILSON, PWF ;
SELHUB, J .
ATHEROSCLEROSIS, 1995, 114 (01) :93-103
[8]   Hyperhomocysteinemia in end-stage renal disease: Prevalence, etiology, and potential relationship to arteriosclerotic outcomes [J].
Bostom, AG ;
Lathrop, L .
KIDNEY INTERNATIONAL, 1997, 52 (01) :10-20
[9]   A QUANTITATIVE ASSESSMENT OF PLASMA HOMOCYSTEINE AS A RISK FACTOR FOR VASCULAR-DISEASE - PROBABLE BENEFITS OF INCREASING FOLIC-ACID INTAKES [J].
BOUSHEY, CJ ;
BERESFORD, SAA ;
OMENN, GS ;
MOTULSKY, AG .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1995, 274 (13) :1049-1057
[10]   HYPERHOMOCYSTEINAEMIA IN STROKE - PREVALENCE, CAUSE, AND RELATIONSHIPS TO TYPE OF STROKE AND STROKE RISK-FACTORS [J].
BRATTSTROM, L ;
LINDGREN, A ;
ISRAELSSON, B ;
MALINOW, MR ;
NORRVING, B ;
UPSON, B ;
HAMFELT, A .
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 1992, 22 (03) :214-221